Will Venetoclax be included in medical insurance in 2023?

After the original drug Venetoclax (Venetoclax) was launched in China, the original drug Venetoclax can be found in the Class B medical insurance directory in 2023, but it is only available for adult acute myeloid leukemia patients for medical insurance reimbursement. Patients who do not meet the conditions need to purchase it at their own expense. The price of each box of 100mg*14 tablets may be around 5,000 yuan.

In the United States, venetoclax is indicated for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and the indication is independent of mutation status (e.g., 17p deletion, IGHV mutation, 12+). In the EU, venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukemia (CLL) with 17p deletion or TP53 mutation in adults who are not suitable for B-cell receptor pathway inhibitors or who have failed B-cell receptor pathway inhibitors, and for the treatment of CLL without 17p deletion or TP53 mutation in adults who have failed both chemoimmunotherapy and B-cell receptor pathway inhibitors. Venetoclax is also part of a combination therapy for acute myeloid leukemia (AML), along with azacitidine, decitabine or low-dose cytarabine in newly diagnosed adults 75 years or older or who have other health problems that preclude intensive chemotherapy.

The Turkish version of Venekraoriginal drug, specifications100mg*112 tablets sold overseas is priced at more than 10,000 yuan per box (the price may fluctuate due to exchange rates), which is even more expensive. Cheaper generic drugs are also sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs. The price of a box of 100mg*120 tablets produced by a Bangladeshi pharmaceutical factory is around RMB 4,000 (prices may fluctuate due to exchange rates).